Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Two-Stage Study to Assess the Efficacy and Safety of 3 Doses of Crofelemer Orally Twice Daily for the Treatment of HIV-Associated Diarrhea

Trial Profile

Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Two-Stage Study to Assess the Efficacy and Safety of 3 Doses of Crofelemer Orally Twice Daily for the Treatment of HIV-Associated Diarrhea

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crofelemer (Primary)
  • Indications Diarrhoea
  • Focus Registrational; Therapeutic Use
  • Acronyms ADVENT
  • Sponsors Salix Pharmaceuticals
  • Most Recent Events

    • 25 Jul 2018 According to RedHill Biopharma media release, top-line results expected in the fourth quarter of 2018
    • 24 Jul 2017 Results published in a Napo Pharmaceuticals media release.
    • 24 Jul 2017 According to a Napo Pharmaceuticals media release, the results of a supplemental analysis were reported at the 9th International AIDS Society (IAS) Conference on HIV Science.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top